Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report.

Annals of hepato-biliary-pancreatic surgery

Lee B, Cho JY, Han HS, Yoon YS, Lee HW, Lee JS, Kim M, Choi Y.
PMID: 34845134
Ann Hepatobiliary Pancreat Surg. 2021 Nov 30;25(4):571-574. doi: 10.14701/ahbps.2021.25.4.571.

Although there is no established desensitization protocol for liver transplantation (LT), desensitization usually entails treatment with rituximab, plasmapheresis, splenectomy, and intravenous immunoglobulin (IVIG) infusion together with a local graft. The desensitization protocol is usually initiated 2 to 3 weeks...

Cite
Lee B, Cho JY, Han HS, et al. Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report. Ann Hepatobiliary Pancreat Surg. 2021;25(4):571-574doi: 10.14701/ahbps.2021.25.4.571.
Lee, B., Cho, J. Y., Han, H. S., Yoon, Y. S., Lee, H. W., Lee, J. S., Kim, M., & Choi, Y. (2021). Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report. Annals of hepato-biliary-pancreatic surgery, 25(4), 571-574. https://doi.org/10.14701/ahbps.2021.25.4.571
Lee, Boram, et al. "Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report." Annals of hepato-biliary-pancreatic surgery vol. 25,4 (2021): 571-574. doi: https://doi.org/10.14701/ahbps.2021.25.4.571
Lee B, Cho JY, Han HS, Yoon YS, Lee HW, Lee JS, Kim M, Choi Y. Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report. Ann Hepatobiliary Pancreat Surg. 2021 Nov 30;25(4):571-574. doi: 10.14701/ahbps.2021.25.4.571. PMID: 34845134; PMCID: PMC8639309.
Copy Download .nbib Format: NLM
Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG).

Research and practice in thrombosis and haemostasis

Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K.
PMID: 30046682
Res Pract Thromb Haemost. 2017 Jun 19;1(1):134-137. doi: 10.1002/rth2.12009. eCollection 2017 Jul.

Delayed onset heparin induced thrombocytopenia (HIT), is characterized by a late nadir due to persistent platelet-activating IgG antibodies. It typically begins or worsens 5 or more days after heparin is discontinued with complications such as thrombosis up to 3...

Cite
Doucette K, DeStefano CB, Jain NA, et al. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost. 2017;1(1):134-137doi: 10.1002/rth2.12009.
Doucette, K., DeStefano, C. B., Jain, N. A., Cruz, A. L., Malkovska, V., & Fitzpatrick, K. (2017). Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Research and practice in thrombosis and haemostasis, 1(1), 134-137. https://doi.org/10.1002/rth2.12009
Doucette, Kimberley, et al. "Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)." Research and practice in thrombosis and haemostasis vol. 1,1 (2017): 134-137. doi: https://doi.org/10.1002/rth2.12009
Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost. 2017 Jun 19;1(1):134-137. doi: 10.1002/rth2.12009. eCollection 2017 Jul. PMID: 30046682; PMCID: PMC6058197.
Copy Download .nbib Format: NLM
Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease.

Korean circulation journal

Lee SM, Lee JB, Go YB, Song HY, Lee BJ, Kwak JH.
PMID: 25469144
Korean Circ J. 2014 Nov;44(6):415-22. doi: 10.4070/kcj.2014.44.6.415. Epub 2014 Nov 25.

BACKGROUND AND OBJECTIVES: Ten to twenty percent of children with Kawasaki disease (KD) do not respond to initial intravenous immunoglobulin (IVIG) treatment. If untreated, approximately 15% to 25% of KD patients have complications. The aim of this study was...

Cite
Lee SM, Lee JB, Go YB, et al. Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease. Korean Circ J. 2014;44(6):415-22doi: 10.4070/kcj.2014.44.6.415.
Lee, S. M., Lee, J. B., Go, Y. B., Song, H. Y., Lee, B. J., & Kwak, J. H. (2014). Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease. Korean circulation journal, 44(6), 415-22. https://doi.org/10.4070/kcj.2014.44.6.415
Lee, Sang Min, et al. "Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease." Korean circulation journal vol. 44,6 (2014): 415-22. doi: https://doi.org/10.4070/kcj.2014.44.6.415
Lee SM, Lee JB, Go YB, Song HY, Lee BJ, Kwak JH. Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease. Korean Circ J. 2014 Nov;44(6):415-22. doi: 10.4070/kcj.2014.44.6.415. Epub 2014 Nov 25. PMID: 25469144; PMCID: PMC4248614.
Copy Download .nbib Format: NLM
Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report.

Annals of hepato-biliary-pancreatic surgery

Lee B, Cho JY, Han HS, Yoon YS, Lee HW, Lee JS, Kim M, Choi Y.
PMID: 34845134
Ann Hepatobiliary Pancreat Surg. 2021 Nov 30;25(4):571-574. doi: 10.14701/ahbps.2021.25.4.571.

Although there is no established desensitization protocol for liver transplantation (LT), desensitization usually entails treatment with rituximab, plasmapheresis, splenectomy, and intravenous immunoglobulin (IVIG) infusion together with a local graft. The desensitization protocol is usually initiated 2 to 3 weeks...

Cite
Lee B, Cho JY, Han HS, et al. Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report. Ann Hepatobiliary Pancreat Surg. 2021;25(4):571-574doi: 10.14701/ahbps.2021.25.4.571.
Lee, B., Cho, J. Y., Han, H. S., Yoon, Y. S., Lee, H. W., Lee, J. S., Kim, M., & Choi, Y. (2021). Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report. Annals of hepato-biliary-pancreatic surgery, 25(4), 571-574. https://doi.org/10.14701/ahbps.2021.25.4.571
Lee, Boram, et al. "Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report." Annals of hepato-biliary-pancreatic surgery vol. 25,4 (2021): 571-574. doi: https://doi.org/10.14701/ahbps.2021.25.4.571
Lee B, Cho JY, Han HS, Yoon YS, Lee HW, Lee JS, Kim M, Choi Y. Long-term outcomes of emergency ABO-incompatible living donor liver transplantation using a modified desensitization protocol for highly sensitized patients with acute liver failure: A case report. Ann Hepatobiliary Pancreat Surg. 2021 Nov 30;25(4):571-574. doi: 10.14701/ahbps.2021.25.4.571. PMID: 34845134.
Copy Download .nbib Format: NLM
Treatment of Susac Syndrome.

Current treatment options in neurology

Vodopivec I, Prasad S.
PMID: 26715396
Curr Treat Options Neurol. 2016 Jan;18(1):3. doi: 10.1007/s11940-015-0386-x.

OPINION STATEMENT: Susac syndrome is a microangiopathy of the brain, retina, and cochlea. Several lines of evidence support the concept that this disease is an acquired autoimmune disorder. Prospective, randomized, controlled studies of treatments are not available because the...

Cite
Vodopivec I, Prasad S. Treatment of Susac Syndrome. Curr Treat Options Neurol. 2016;18(1):3doi: 10.1007/s11940-015-0386-x.
Vodopivec, I., & Prasad, S. (2016). Treatment of Susac Syndrome. Current treatment options in neurology, 18(1), 3. https://doi.org/10.1007/s11940-015-0386-x
Vodopivec, Ivana, and Prasad, Sashank. "Treatment of Susac Syndrome." Current treatment options in neurology vol. 18,1 (2016): 3. doi: https://doi.org/10.1007/s11940-015-0386-x
Vodopivec I, Prasad S. Treatment of Susac Syndrome. Curr Treat Options Neurol. 2016 Jan;18(1):3. doi: 10.1007/s11940-015-0386-x. PMID: 26715396.
Copy Download .nbib Format: NLM
Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient.

Nephro-urology monthly

Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami MR, Jafari A.
PMID: 26034746
Nephrourol Mon. 2015 May 23;7(3):e27073. doi: 10.5812/numonthly.7(3)2015.27073. eCollection 2015 May.

BACKGROUND: Antibody mediated rejection (AMR) and thrombotic microangiopathy (TMA) after kidney transplantation are difficult to differentiate most of the times and both play important roles in kidney allograft loss. Common treatment strategies of these two conditions include plasmapheresis, intravenous...

Cite
Dashti-Khavidaki S, Shojaie L, Hosni A, et al. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephrourol Mon. 2015;7(3):e27073doi: 10.5812/numonthly.7(3)2015.27073.
Dashti-Khavidaki, S., Shojaie, L., Hosni, A., Khatami, M. R., & Jafari, A. (2015). Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephro-urology monthly, 7(3), e27073. https://doi.org/10.5812/numonthly.7(3)2015.27073
Dashti-Khavidaki, Simin, et al. "Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient." Nephro-urology monthly vol. 7,3 (2015): e27073. doi: https://doi.org/10.5812/numonthly.7(3)2015.27073
Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami MR, Jafari A. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephrourol Mon. 2015 May 23;7(3):e27073. doi: 10.5812/numonthly.7(3)2015.27073. eCollection 2015 May. PMID: 26034746; PMCID: PMC4450162.
Copy Download .nbib Format: NLM
Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose "IVIG-SN" Therapy for Pediatric Patients with Kawasaki Disease.

Korean circulation journal

Yoon KL, Lee HY, Yu JJ, Lee JY, Han MY, Kim KY, Huh J.
PMID: 28382076
Korean Circ J. 2017 Mar;47(2):209-214. doi: 10.4070/kcj.2016.0139. Epub 2017 Mar 10.

BACKGROUND AND OBJECTIVES: Intravenous immunoglobulin-SN (IVIG-SN) is a new human immunoglobulin product. Its safety is ensured by pathogen-elimination steps comprising solvent/detergent treatment and a nanofiltration process. This multicenter clinical study was designed to evaluate the efficacy and safety of...

Cite
Yoon KL, Lee HY, Yu JJ, et al. Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose "IVIG-SN" Therapy for Pediatric Patients with Kawasaki Disease. Korean Circ J. 2017;47(2):209-214doi: 10.4070/kcj.2016.0139.
Yoon, K. L., Lee, H. Y., Yu, J. J., Lee, J. Y., Han, M. Y., Kim, K. Y., & Huh, J. (2017). Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose "IVIG-SN" Therapy for Pediatric Patients with Kawasaki Disease. Korean circulation journal, 47(2), 209-214. https://doi.org/10.4070/kcj.2016.0139
Yoon, Kyung Lim, et al. "Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose "IVIG-SN" Therapy for Pediatric Patients with Kawasaki Disease." Korean circulation journal vol. 47,2 (2017): 209-214. doi: https://doi.org/10.4070/kcj.2016.0139
Yoon KL, Lee HY, Yu JJ, Lee JY, Han MY, Kim KY, Huh J. Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose "IVIG-SN" Therapy for Pediatric Patients with Kawasaki Disease. Korean Circ J. 2017 Mar;47(2):209-214. doi: 10.4070/kcj.2016.0139. Epub 2017 Mar 10. PMID: 28382076; PMCID: PMC5378027.
Copy Download .nbib Format: NLM
A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid.

Oman medical journal

Al-Kathiri L, Mercyamma V, Al-Najjar T.
PMID: 30038738
Oman Med J. 2018 Jul;33(4):356-359. doi: 10.5001/omj.2018.65.

Toxic epidermal necrolysis (TEN), a severe form of Stevens-Johnson syndrome, is an acute life-threatening adverse drug reaction with a mortality rate of approximately 30%. Primary treatment of TEN is usually supportive. The use of intravenous immunoglobulin (IVIG) and corticosteroids...

Cite
Al-Kathiri L, Mercyamma V, Al-Najjar T. A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid. Oman Med J. 2018;33(4):356-359doi: 10.5001/omj.2018.65.
Al-Kathiri, L., Mercyamma, V., & Al-Najjar, T. (2018). A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid. Oman medical journal, 33(4), 356-359. https://doi.org/10.5001/omj.2018.65
Al-Kathiri, Lutfi, et al. "A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid." Oman medical journal vol. 33,4 (2018): 356-359. doi: https://doi.org/10.5001/omj.2018.65
Al-Kathiri L, Mercyamma V, Al-Najjar T. A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid. Oman Med J. 2018 Jul;33(4):356-359. doi: 10.5001/omj.2018.65. PMID: 30038738; PMCID: PMC6047178.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries